Page 12 - Binder2

Depending on the drug, this happens in up to 30% of
patients. And yet, the industry's answer is always the same:

• Increase the dose.
• Add another drug.
• Switch to the next biologic drug.

But what if the problem isn’t the patient—or even the
disease?

What if the biologics themselves are flawed?

Despite the hype, these drugs are expensive to make,
fragile to deliver, and often unsustainable for long-term
use.

However, we’ve built an entire ecosystem—from
biomanufacturing to regulatory frameworks—around
molecules that were never designed to work in harmony
with the human immune system.

This book is about that reckoning.

It begins when most stories end: when a biologic drug fails.

This book asks why we’ve accepted short-lived therapies as
the standard, and why tolerization remains a clinical
afterthought rather than a call to action. It explores the
science behind immune rejection, the economics that keep
broken healthcare systems alive, and the silence that shields
it all.

10